Clinical Trial

A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Due to procedural adjustments at the investigative site, domestic registration on the China health authority's platform must be finalized prior to re-submission on ClinicalTrials.gov. Therefore, we hereby withdraw the current submission.
Summary
This study adopts a single-center, single-arm, open-label design. It aims to evaluate the safety and tolerability of GT307 in patients with advanced solid tumors, as well as assess its pharmacokinetic profile and efficacy, and determine the optimal dosage regimen.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-06-10
notable Enrollment reduced: 16 -> 0 participants 2026-06-10
Trial Details
NCT Number NCT07534813
Lead Sponsor Grit Biotechnology
Collaborators: Fudan University
Conditions Advanced Solid Tumors
Start Date 2026-04-30
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09